27 results about "Opioid overdose" patented technology

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

A portable emergency response kit designed for rapid intervention in opioid overdose or cardiac arrest scenarios comprises a durable case with compartments for specific medical devices, such as opioid overdose treatment medication or an Automated External Defibrillator (AED). The case features a breakable closed circuit that is, upon opening, triggered to send a signal to notify emergency medical services (EMS) or predefined contacts of the kit's location.The system utilizes GPS module and may include dual-mode communication capabilities for reliable alert transmission in various environments. Additional features may include a transparent case material for visual confirmation of contents, tamper-evident seals, QR codes linked to instructional content, and a battery power source. The kit is designed to be user-friendly, incorporating ergonomic elements and optional accessories for enhanced portability and storage, ensuring rapid and effective response in critical situations.

Methods and apparatuses for opioid overdose prevention are described. The apparatus comprises a memory and at least one processor coupled to the memory. The processor is configured to receive one or more measurements related to one or more vitals of a user, and cause, based on the one or more measurements, administration of a first dose of an overdose prevention medication to the user.

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are negative allosteric modulators of the p-opioid receptor (MOR). Also disclosed are methods of inhibiting MOR as well as treating opioid overdose.

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

A wearable device is provided for recognition and response to an overdose, such as an opioid overdose. The device includes an oximetry sensor for measuring peripheral oxygen saturation (SpO2) of a wearer of the wearable device and a motion sensor for determining whether the wearer of the wearable device is moving or motionless. The wearable device further includes an injector including a supply of an antidote and a needle for intramuscular delivery of the antidote to the wearer of the wearable device. The wearable device may also include a housing in which the oximetry sensor, the motion sensor, and the supply of the antidote is contained and in which the needle is initially contained in a retracted condition. The wearable device may further include a strap extending from the housing and sized to secure the housing on an upper arm of the wearer adjacent the shoulder of the wearer.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

Naloxone variants that are both long lasting and responsive are disclosed. One version of the compound has a boron ester functional group and the antagonist compound is capable of a sustained release of antagonist based on reaction with hydrogen peroxide. In addition, a method of treating opioid overdose is disclosed. The method involves administering a therapeutically effective amount of the formulation described above to a patient in need thereof. Administration occurs either intranasally, sublingually or intranasally and sublingually, wherein if administration occurs intranasally and sublingually administration occurs simultaneously, sequentially or concomitantly.

Disclosed herein compositions comprising setmelanotide (SET) and methods of using those compositions to prevent and / or minimize one or more indexes of opioid-induced respiratory depression (OIRD) in a clinical setting and in an opioid overdose.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The Overdose Reviver Pressurized Spray, provides two different methods to administer Narcan solution intranasally, containing enough Narcan solution, and pressurized air for at least ten one second 4 mg squirts of Narcan solution with or without a 3″ long extension air tube. To aim from the base of a nostril, depress an atomizing air release valve, administering atomized, pressurized Narcan solution into the nostrils of an unconscious, opioid overdosed person. Or to remove an air release valve, insert a pressurized air canister with Narcan solution into The Overdose Reviver Automatic Inhaler, supplying the necessary pressurized air, and Narcan solution for an Automatic Inhaler to perform its automatic reviving method. Wherein a microprocessor chip detects a life-threatening low heart rate, an Automatic Inhaler will automatically, repeatedly, administer atomized, pressurized Narcan solution into the nostrils of an unconscious opioid overdosed person once every two to three minutes and alert for help.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when opioid induced respiratory depression is detected. The system and methods include a wearable device that acquires physiological and other information from an opioid user during an opioid use session, analyzes the information to detect the presence of opioid induced respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.

An intelligent dosing platform system for emergency medication administration comprising intelligent injection devices with emergency protocol modules, time-based tracking systems, and AI-driven prompting systems. The system analyzes time-based administration protocols for emergency medications, monitors elapsed time since previous medication administrations, and generates next dose prompts based on protocol timing requirements and elapsed time data. A field coordination module transmits administration timing data between field emergency response teams and remote coordination systems. The system supports emergency response environments including cardiac emergencies, anaphylaxis, opioid overdose response, and military field operations. Multi-modal alert systems deliver dose prompts through audible alerts, visual electronic medical record prompts, and remote physician communications. The system prevents duplicate medication administration across emergency response teams through timing data sharing while accounting for time delays caused by patient movement and transport.

Compounds having opioid characteristics are provided that can be used for various therapeutic methods including the treatment of pain and opioid use disorders, and compounds having opioid antagonist properties that can be used to treat opioid overdoses. These compounds include agonists and antagonists having selective activity toward more one or more opioid receptors. Such compounds can be full or partial agonists, or can be antagonists lacking agonist properties toward delta and kappa opioid receptors. The partial agonists can diminish side effects associated with traditional opioid medications, and the antagonists can overcome respiratory depression caused by potent narcotics. Structurally these compounds include constrained piperidines with alkenyl or cyanoalkyl groups, as well as other substituents providing desired properties.

This disclosure provides devices, delivery systems, medicaments, and methods for use to rescue a subject identified in need thereof from opioid overdose. In certain embodiments, the device is an injection device (such as, an autoinjector) for intramuscular or subcutaneous administration of a medicament comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof.

Naloxone is commonly used to treat opioid overdose. The present invention presents a combination of naloxone with atipamezole. The invention presents various dosage forms to be administered parenterally, orally or topically. The formulations may also contain a chelating agent such as disodium EDTA. These combination formulations can be used to treat drug addicts.

This disclosure describes opioid-specific monoclonal antibodies (mAb), methods of making those antibodies, and methods of using those antibodies. The methods include, for example, treating a subject with an opioid use disorder or neonatal opioid withdrawal syndrome or preventing and reversing opioid overdose in a subject. Additionally or alternatively, the antibodies may be used to detect opioids including, for example, in a screening, diagnostic, or forensic assay.

The present invention relates to a formulation delivery system designed to deliver formulations through a removable cartridge that houses an atomizer and wick assembly. The system is adaptable for multiple medications and environments, including wearable devices such as masks, helmets, and protective suits. The removable cartridge ensures controlled, consistent delivery of medications, including solutions, suspensions, and emulsions. Key features include air-tight seals, sensor technology for cartridge detection and dosage control, and a modular design that allows easy replacement or refilling. This system addresses the challenges of traditional nebulizers by improving portability, ease of use, and precision. It is particularly suited for patients with chronic respiratory conditions or emergency situations where rapid medication delivery, such as naloxone for opioid overdoses, is crucial. The system is also integrated with modern technologies, offering real-time monitoring and feedback to ensure user safety and compliance.

The disclosure provides, inter alia, opioid haptens, opioid hapten conjugates, opioid vaccines, methods of treating or preventing opioid use disorder, methods of treating opioid overdose, and methods of generating and / or isolating antibodies selective for opioids.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when detected. The system employs a progressive challenge-response system to detect unresponsiveness, deliver physical stimuli, administer one or more doses of an antidote, and transmit notifications, thereby improving survival rates in overdose situations. The system and methods include a wearable device that acquires physiological information from an opioid user during an opioid use session, analyzes the information to detect respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and / or at least one symptom thereof.

Morphine derivative comprise a modification of the framework of the molecule, wherein the derivative possesses novel bioactivity profiles that are different from morphine, and can address pain without an associated untoward effect, such as respiratory depression, addiction, etc., or may be used to treat pain without an addictive side effect or respiratory depression, or may be applied as an alternative to naloxone for addressing opioid overdose.

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and / or at least one symptom thereof.

Disclosed herein are methods of using compounds that allosterically modulate the μ-opioid receptor (MOD) or cannabinoid receptor 1 (CB1) to treat pain (for positive allosteric modulators) or to treat opioid overdoses (for negative allosteric modulators).

The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

Described herein are i) sequestering agents and ii) central nervous system (CNS) active agents for the treatment of intoxication due to toxic agents such as drugs of abuse, and associated symptoms. Also disclosed herein, are a cucurbituril and naloxone for use in the treatment of opioid overdoses through sequestering and excretion of the bound molecule of interest through the urine. Also provided herein, are kits and methods of treatment of the disclosure.